Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-03-11

Clinical Trial Update: Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluating the clinical effectiveness of a 10 cm^2 rivastigmine transdermal patch in Alzheimer's disease have been reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2011-03-11